Adderall Buyers Slam Drugmaker's Class Cert. Objections

By Melissa Lipman (September 14, 2015, 3:31 PM EDT) -- Consumers accusing Shire US Inc. of paying off generic rivals to delay selling cheaper versions of Adderall defended their bid for class certification in the antitrust suit Friday, arguing that under the drugmaker's logic it would be impossible to ever certify a consumer class action over pharmaceuticals.

The plaintiffs have been fighting for class status since June for their claims that Shire inked pay-for-delay settlements in sham patent litigation against Teva Pharmaceuticals USA Inc. and Impax Laboratories Inc. to stave off competition from generic versions of the blockbuster attention deficit hyperactivity disorder drug.

The purchasers argued in their latest filing that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!